<VariationArchive VariationID="1774" VariationName="MSH2, 32-KB DEL, EX1-6" VariationType="Deletion" Accession="VCV000001774" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2013-04-04" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="16813" VariationID="1774">
      <GeneList>
        <Gene Symbol="MSH2" FullName="mutS homolog 2" GeneID="4436" HGNC_ID="HGNC:7325" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>2p21-16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47403067" stop="47709830" display_start="47403067" display_stop="47709830" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47630205" stop="47710366" display_start="47630205" display_stop="47710366" Strand="+" />
          </Location>
          <OMIM>609309</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>MSH2, 32-KB DEL, EX1-6</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p21</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47618487" stop="47650860" display_start="47618487" display_stop="47650860" variantLength="32374" />
      </Location>
      <OtherNameList>
        <Name>32-KB DEL, EX1-6</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.47618487_47650860delinsN[155]" Assembly="GRCh37">
            <Expression>NC_000002.11:g.47618487_47650860delinsN[155]</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="MSH2_001602" DB="LOVD 3" />
        <XRef Type="Allelic variant" ID="609309.0023" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff provided an HGVS expression for allelic variant 609309.0023 as reported by https://lovd.nl/MSH2_001602.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="MSH2, 32-KB DEL, EX1-6 AND Muir-Torré syndrome" Accession="RCV000001845" Version="3">
        <ClassifiedConditionList TraitSetID="452">
          <ClassifiedCondition DB="MedGen" ID="C1321489">Muir-Torré syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2007-02-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="MSH2, 32-KB DEL, EX1-6 AND Lynch syndrome 1" Accession="RCV000023766" Version="3">
        <ClassifiedConditionList TraitSetID="451">
          <ClassifiedCondition DB="MedGen" ID="C2936783">Lynch syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2007-02-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2007-02-01" NumberOfSubmissions="2" NumberOfSubmitters="1" DateCreated="2013-04-04" MostRecentSubmission="2024-06-09">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">14994245</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15942939</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17250661</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="452" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3222" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Muir-Torre syndrome</ElementValue>
                <XRef ID="MONDO:0008018" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cutaneous sebaceous neoplasms and keratoacanthomas multiple with gastrointestinal and other carcinomas</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MSH2-Related Muir-Torre Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MLH1-Related Muir-Torre Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Muir-Torré syndrome</ElementValue>
                <XRef ID="Keratoacanthoma/3972" DB="Genetic Alliance" />
                <XRef ID="403824007" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MRTES</ElementValue>
                <XRef Type="MIM" ID="158320" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6821" />
                <XRef ID="6821" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514728" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514729" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515534" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528914" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556509" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529017" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528339" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518997" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501399" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528930" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="review" Abbrev="Ponti, 2005">
                <ID Source="PubMed">15662714</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCRS, 2001">
                <ID Source="PubMed">11598466</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="SGO, 2014">
                <URL>https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer</URL>
                <CitationText>Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="NSGC/CCA-ICC, 2012">
                <ID Source="PubMed">22167527</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="587" DB="Orphanet" />
              <XRef ID="C1321489" DB="MedGen" />
              <XRef ID="MONDO:0008018" DB="MONDO" />
              <XRef Type="MIM" ID="158320" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="451" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2582" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MSH2-Related Hereditary Non-Polyposis Colon Cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Lynch syndrome 1</ElementValue>
                <XRef ID="MONDO:0007356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MSH2-Related Lynch Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Colorectal cancer, hereditary, nonpolyposis, type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lynch syndrome I</ElementValue>
                <Citation Type="general" Abbrev="Vasen et al., 2007">
                  <ID Source="pmc">2740877</ID>
                </Citation>
                <XRef ID="Colorectal+Cancer%2C+Hereditary+Nonpolyposis%2C+Type+1/1748" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary non-polyposis colorectal cancer, type 1</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FCC1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HNPCC1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518997" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000510683" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518999" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501399" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514729" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15052" />
                <XRef ID="15052" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="Vasen et al., 2007">
                <ID Source="pmc">2740877</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCRS, 2001">
                <ID Source="PubMed">11598466</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987434</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="AMA/NCHPEG, 2012">
                <URL>http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf</URL>
              </Citation>
              <Citation Type="practice guideline" Abbrev="SGO, 2014">
                <URL>https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer</URL>
                <CitationText>Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="MSTF, 2014">
                <ID Source="PubMed">25070057</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO/ESMO, 2015">
                <ID Source="PubMed">25452455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2014">
                <ID Source="PubMed">24310308</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mork et al., 2015">
                <ID Source="PubMed">25711197</ID>
              </Citation>
              <Citation Type="general" Abbrev="Dutch SCG, 2013">
                <ID Source="PubMed">23535968</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mallorca group, 2013">
                <ID Source="PubMed">23408351</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC/CCA-ICC, 2012">
                <ID Source="PubMed">22167527</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Colon-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Lynch-Syndrome.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, MLH1, MSH2, MSH6, PMS2, EPCAM Pathogenic Variants, Lynch Syndrome (Hereditary Non-polyposis Colon Cancer [HNPCC]), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <XRef ID="144" DB="Orphanet" />
              <XRef ID="C2936783" DB="MedGen" />
              <XRef ID="MONDO:0007356" DB="MONDO" />
              <XRef Type="MIM" ID="120435" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="22001" SubmissionDate="2013-03-26" DateLastUpdated="2024-06-09" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="609309.0023_MUIR-TORRE SYNDROME" title="MSH2, 32-KB DEL, EX1-6_MUIR-TORRE SYNDROME" />
        <ClinVarAccession Accession="SCV000022001" DateUpdated="2024-06-09" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2007-02-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Barana et al. (2004) identified a 32-kb deletion involving exons 1-6 of the MSH2 gene in 3 affected members in 2 generations of an Italian family with Muir-Torre syndrome (MRTES; 158320). The father had 2 metachronous colon cancers starting at age 53 years, a daughter had a colon and ovarian cancer starting at age 42 years, and a son had an adenoma with a focus of carcinoma at age 47 years. All 3 affected members presented with cutaneous lesions characteristic of MRTES.</Attribute>
              <Citation>
                <ID Source="PubMed">14994245</ID>
              </Citation>
              <XRef DB="OMIM" ID="158320" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In affected and asymptomatic members of a 4-generation Italian family (family C) with hereditary nonpolyposis colorectal cancer (LYNCH1; 120435), Stella et al. (2007) identified a 32-kb deletion with identical breakpoints to that found by Barana et al. (2004) and van der Klift et al. (2005) in 2 branches of an unrelated 5-generation Italian family (family V+Va); both families and 2 unrelated patients with HNPCC carrying the 32-kb deletion were from the Veneto region of Italy. Haplotype analysis of the 2 families suggested that the MSH2 exon 1-6 deletion is probably a founder mutation. Stella et al. (2007) noted that skin cancers, including 4 keratoacanthomas, had been reported in 10 of the 19 affected members of family V+Va, and 1 patient from family C had a squamous cell acanthoma. Families V and Va, which had previously been described by Barana et al. (2004) and van der Klift et al. (2005) (family It1), respectively, were found to be branches of the same large Italian family described by Stella et al. (2007).</Attribute>
              <Citation>
                <ID Source="PubMed">17250661</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">14994245</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">15942939</ID>
              </Citation>
              <XRef DB="OMIM" ID="120435" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <Name>MSH2, 32-KB DEL, EX1-6</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">32-KB DEL, EX1-6</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="609309.0023" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">MUIR-TORRE SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9796638" SubmissionDate="2022-11-15" DateLastUpdated="2024-06-09" DateCreated="2024-06-09">
        <ClinVarSubmissionID localKey="609309.0023_LYNCH SYNDROME 1" title="MSH2, 32-KB DEL, EX1-6_LYNCH SYNDROME 1" />
        <ClinVarAccession Accession="SCV005046824" DateUpdated="2024-06-09" DateCreated="2024-06-09" Type="SCV" Version="1" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2007-02-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Barana et al. (2004) identified a 32-kb deletion involving exons 1-6 of the MSH2 gene in 3 affected members in 2 generations of an Italian family with Muir-Torre syndrome (MRTES; 158320). The father had 2 metachronous colon cancers starting at age 53 years, a daughter had a colon and ovarian cancer starting at age 42 years, and a son had an adenoma with a focus of carcinoma at age 47 years. All 3 affected members presented with cutaneous lesions characteristic of MRTES.</Attribute>
              <Citation>
                <ID Source="PubMed">14994245</ID>
              </Citation>
              <XRef DB="OMIM" ID="158320" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In affected and asymptomatic members of a 4-generation Italian family (family C) with hereditary nonpolyposis colorectal cancer (LYNCH1; 120435), Stella et al. (2007) identified a 32-kb deletion with identical breakpoints to that found by Barana et al. (2004) and van der Klift et al. (2005) in 2 branches of an unrelated 5-generation Italian family (family V+Va); both families and 2 unrelated patients with HNPCC carrying the 32-kb deletion were from the Veneto region of Italy. Haplotype analysis of the 2 families suggested that the MSH2 exon 1-6 deletion is probably a founder mutation. Stella et al. (2007) noted that skin cancers, including 4 keratoacanthomas, had been reported in 10 of the 19 affected members of family V+Va, and 1 patient from family C had a squamous cell acanthoma. Families V and Va, which had previously been described by Barana et al. (2004) and van der Klift et al. (2005) (family It1), respectively, were found to be branches of the same large Italian family described by Stella et al. (2007).</Attribute>
              <Citation>
                <ID Source="PubMed">17250661</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">14994245</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">15942939</ID>
              </Citation>
              <XRef DB="OMIM" ID="120435" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <Name>MSH2, 32-KB DEL, EX1-6</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">32-KB DEL, EX1-6</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="609309.0023" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">LYNCH SYNDROME 1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="22001" TraitType="Disease" MappingType="Name" MappingValue="MUIR-TORRE SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C1321489" Name="Muir-Torré syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9796638" TraitType="Disease" MappingType="Name" MappingValue="LYNCH SYNDROME 1" MappingRef="Alternate">
        <MedGen CUI="C2936783" Name="Lynch syndrome 1" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2024-06-02">SCV000045057</Accession>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

